You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

WELLBUTRIN XL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Wellbutrin Xl patents expire, and when can generic versions of Wellbutrin Xl launch?

Wellbutrin Xl is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in WELLBUTRIN XL is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Wellbutrin Xl

A generic version of WELLBUTRIN XL was approved as bupropion hydrochloride by APNAR PHARMA LP on February 7th, 2000.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for WELLBUTRIN XL?
  • What are the global sales for WELLBUTRIN XL?
  • What is Average Wholesale Price for WELLBUTRIN XL?
Summary for WELLBUTRIN XL
Drug patent expirations by year for WELLBUTRIN XL
Drug Prices for WELLBUTRIN XL

See drug prices for WELLBUTRIN XL

Recent Clinical Trials for WELLBUTRIN XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 1
Mclean HospitalPhase 4
Kenya Medical Research InstitutePhase 4

See all WELLBUTRIN XL clinical trials

Pharmacology for WELLBUTRIN XL
Paragraph IV (Patent) Challenges for WELLBUTRIN XL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
WELLBUTRIN XL Extended-release Tablets bupropion hydrochloride 150 mg and 300 mg 021515 1 2004-09-21

US Patents and Regulatory Information for WELLBUTRIN XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-001 Aug 28, 2003 AB3 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-002 Aug 28, 2003 AB3 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for WELLBUTRIN XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-002 Aug 28, 2003 ⤷  Sign Up ⤷  Sign Up
Bausch WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-001 Aug 28, 2003 ⤷  Sign Up ⤷  Sign Up
Bausch WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-002 Aug 28, 2003 ⤷  Sign Up ⤷  Sign Up
Bausch WELLBUTRIN XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 021515-001 Aug 28, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.